Research Projects & Grants

College/University

  • Phase II trial of serum Micro RNA-371 in detecting active germ cell tumors in patients with suspected regional disease –(MAGESTIC Trial: MiRNA in detecting Active Germ cell tumors in Early Suspected and metastaTIC disease Trial), Role: Investigator, University of Southern California, (10/2024 - 10/2025) Status: Approved

Default Sponsor Type

  • Phase II trial of serum Micro RNA-371 in detecting active germ cell tumors in patients with suspected regional disease –(MAGESTIC Trial: MiRNA in detecting Active Germ cell tumors in Early Suspected and metastaTIC disease Trial), Role: Investigator, University of Southern California, (10/2024 - 10/2025) Status: Approved

For Profit Organization

  • UroGen BL011: A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence, Role: PI, UroGen Ltd., (04/2025 - 04/2026) Status: Approved
  • SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer, Role: Investigator, Southwest Oncology Group, (04/2024 - 09/2024) Status: Completed
  • UroGen BL006: A randomized, controlled, open-label study of the efficacy, durability, and safety of UGN-102 with or without TURBT in patients with low grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC) (ATLAS), Role: PI, UroGen Ltd., (03/2023 - 03/2024) Status: Completed
  • UroGen Pharma Ltd. BL007: A Rollover Study to Follow the Durability of Response for Patients from Study UT001 (Formerly TC- UT-03, Post marketing Commitment) and Study TC-BC-12, Role: PI, UroGen Ltd., (02/2021) Status: Approved
  • UroGen Pharma Ltd.-TC-UT-03-P: A Phase 3 multicenter trial evaluating the efficacy and safety of MitoGel™ (UGN-101) on ablation of upper urinary tract urothelial carcinoma, Role: PI, UroGen Ltd., (04/2020 - 04/2021) Status: Completed
  • UroGen TC-BC-12: A phase 2b, Single-arm, multicenter trial to evaluate the efficacy and safety of UGN-102 as primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at intermediate risk of recurrence, Role: PI, UroGen Ltd., (04/2020 - 04/2021) Status: Completed
  • Adelphi Values VK8373AUS: Patients experience in treatment for low-grade upper tract Urothelial Carcinoma, Role: PI, Adelphi Values LLC, (10/2019) Status: Completed
  • An Interview Study Designed to Identify, Describe, and Substatiate Important and Relevant Concepts Related to (1) the Signs, Symptoms, and Impacts of Low Grade Upper Tract Urothelial Carcinoma (LG UTUC); (2) Treatment Burden and Patients' Current Treatment Experiences for LG UTUC; and (3) Perceptions of UGN-101 Treatment, from the Perspective of US-based Adults with LG UTUC, Role: PD/PI, Adelphi Values LLC, (10/2019 - 10/2020) Status: Closed
  • SunRISe-2: A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy, Role: PI, Janssen Research & Development, LLC, (09/2024 - 09/2025) Status: Approved
  • UroGen BL013: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low Grade (LG) Non muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (UTOPIA), Role: PI, UroGen Ltd., (11/2024 - 11/2025) Status: Approved

Internal

  • EVALUATING THE RELATIONSHIP BETWEEN THE MICROBIOME AND PROSTATIC DISEASE, Role: Investigator, LLU Dept. of Urology, (05/2024) Status: Approved
  • Clinical Outcomes of Ureteral Stenting For Non-Urologic Procedures, Role: Investigator, LLU Dept. of Urology, (04/2024) Status: Approved
  • THE EFFECT OF ILEAL MICRO BI OT A PROFILES ON POSTOPERATIVE OUTCOMES IN RADICAL CYSTECTOMY PATIENTS, Role: Investigator, LLU Dept. of Urology, (03/2024) Status: Approved
  • 4T-14-1: Surgery in early metastatic seminoma (SEMS): Phase II trials of retroperitoneal lymph node dissection as first-line treatment for testicular seminoma with isolated retroperitoneal disease (1-3cm), Role: PI, LLU Dept. of Urology, (10/2024 - 10/2025) Status: Approved
  • Outcomes of Cystectomy and Urinary Diversion in Patients with Prior Pelvic Radiotherapy, Role: PI, LLU Dept. of Urology, (08/2023) Status: Approved
  • Endoscopic and Nephron Sparing Treatment of Upper Tract Urothelial Carcinoma, Role: PI, LLU Dept. of Urology, (10/2022) Status: Approved
  • Proton beam vs photon radiation therapy for bladder cancer, Role: Investigator, LLU Dept. of Radiation Medicine, (12/2020) Status: Approved
  • Analysis of Perivesical Lymph Nodes after Cystectomy, Role: PI, LLU Dept. of Urology, (08/2020 - 10/2022) Status: Completed
  • Retrospective review of perioperative and oncologic outcomes in patients after nephrectomy and cystectomy, Role: PI, LLU Dept. of Urology, (05/2020) Status: Approved
  • LLU Cancer Center biospecimen laboratory - specimens collection protocol, Role: Investigator, LLU Cancer Institute, (09/2024 - 09/2025) Status: Approved
  • Randomized Single-Blinded Trial of Patient Reported Experiences with Sparing ExteRnal Oblique Fascia Vs Standard Inguinal OrchiEctomy (PRESERVE Trial), Role: Investigator, LLU Dept. of Urology, (03/2025) Status: Approved
  • Investigation on the Social and Psychological Impact of Germ Cell Testicular Cancer Among Survivors, Role: Investigator, LLU Dept. of Urology, (04/2025) Status: Approved